Suppr超能文献

审视多发性硬化症患者未被满足的需求。

Reviewing the Unmet Needs of Patients with Multiple Sclerosis.

作者信息

Mehr Stanton R, Zimmerman Marj P

机构信息

President, SM Health Communications, Newtown, PA.

President, RxDirections, Bucyrus, KS.

出版信息

Am Health Drug Benefits. 2015 Nov;8(8):426-31.

Abstract

Significant innovations in the treatment of patients with multiple sclerosis (MS) have primarily addressed the frequency of flare-ups in relapsing-remitting MS (RRMS). Many advances have been made in this area, and the medical community may be on the verge of a serious discussion of what constitutes a truly effective MS treatment. Certainly, it is important to further delay MS flare-ups and more effectively treat RRMS symptoms. However, great strides in reducing or preventing MS-related disability and providing neuroprotection have been elusive. Many unmet needs are still voiced by patients with MS, clinicians, and caregivers. Current information on the need for progress in various areas is reviewed in this article, including psychosocial care, treatments for progressive MS, biomarker identification, functional outcome measures, individualization of treatment, reducing side effects of medications, and improving medication adherence.

摘要

多发性硬化症(MS)患者治疗方面的重大创新主要针对复发缓解型多发性硬化症(RRMS)的发作频率。该领域已取得诸多进展,医学界可能即将展开一场关于何为真正有效MS治疗的严肃讨论。当然,进一步延缓MS发作并更有效地治疗RRMS症状很重要。然而,在减少或预防MS相关残疾以及提供神经保护方面取得的巨大进展却难以实现。MS患者、临床医生和护理人员仍表达了许多未满足的需求。本文综述了当前关于各个领域取得进展必要性的信息,包括心理社会护理、进行性MS的治疗、生物标志物识别、功能结局测量、治疗个体化、减少药物副作用以及提高药物依从性。

相似文献

1
Reviewing the Unmet Needs of Patients with Multiple Sclerosis.
Am Health Drug Benefits. 2015 Nov;8(8):426-31.
2
Unmet needs of multiple sclerosis patients in the community.
Mult Scler Relat Disord. 2015 Mar;4(2):144-50. doi: 10.1016/j.msard.2015.01.003. Epub 2015 Feb 3.
3
Treatment of relapsing-remitting multiple sclerosis: current approaches and unmet needs.
Curr Opin Neurol. 2012 Feb;25 Suppl:S4-10. doi: 10.1097/01.wco.0000413319.87092.19.
4
Rituximab for relapsing-remitting multiple sclerosis.
Cochrane Database Syst Rev. 2013 Dec 6;2013(12):CD009130. doi: 10.1002/14651858.CD009130.pub3.
5
Teriflunomide for multiple sclerosis.
Cochrane Database Syst Rev. 2012 Dec 12;12:CD009882. doi: 10.1002/14651858.CD009882.pub2.
6
Rapid foot-tapping but not hand-tapping ability is different between relapsing-remitting and progressive multiple sclerosis.
Mult Scler Relat Disord. 2020 Jun;41:102031. doi: 10.1016/j.msard.2020.102031. Epub 2020 Feb 27.
7
Mitoxantrone: a review of its use in multiple sclerosis.
CNS Drugs. 2004;18(6):379-96. doi: 10.2165/00023210-200418060-00010.
9
Genetic differences between primary progressive and relapsing-remitting multiple sclerosis: The impact of immune-related genes variability.
Mult Scler Relat Disord. 2019 Apr;29:130-136. doi: 10.1016/j.msard.2019.01.033. Epub 2019 Jan 24.
10
Cognitive symptoms and correlates of physical disability in individuals with multiple sclerosis.
J Neurosci Nurs. 2003 Dec;35(6):314-20. doi: 10.1097/01376517-200312000-00005.

引用本文的文献

2
Potential Application of Plant-Derived Compounds in Multiple Sclerosis Management.
Nutrients. 2024 Sep 5;16(17):2996. doi: 10.3390/nu16172996.
3
Astroglial connexin 43 is a novel therapeutic target for chronic multiple sclerosis model.
Sci Rep. 2024 May 13;14(1):10877. doi: 10.1038/s41598-024-61508-2.
6
Needs of Persons with Neurological Disorders.
Indian J Psychiatr Soc Work. 2018 Jan;9(1):29-37.
7
The use of alemtuzumab in patients with relapsing-remitting multiple sclerosis: the Gulf perspective.
Ther Adv Neurol Disord. 2020 Sep 16;13:1756286420954119. doi: 10.1177/1756286420954119. eCollection 2020.
8
Treatment Effectiveness for Resolution of Multiple Sclerosis Relapse in a US Health Plan Population.
Neurol Ther. 2019 Dec;8(2):383-395. doi: 10.1007/s40120-019-00156-5. Epub 2019 Sep 28.
9
Cladribine tablets' potential role as a key example of selective immune reconstitution therapy in multiple sclerosis.
Degener Neurol Neuromuscul Dis. 2018 May 3;8:35-44. doi: 10.2147/DNND.S161450. eCollection 2018.
10
Therapies for mobility disability in persons with multiple sclerosis.
Expert Rev Neurother. 2018 Jun;18(6):493-502. doi: 10.1080/14737175.2018.1478289. Epub 2018 May 30.

本文引用的文献

1
Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.
Cochrane Database Syst Rev. 2015 Sep 18;2015(9):CD011381. doi: 10.1002/14651858.CD011381.pub2.
2
Acute optic neuritis: Unmet clinical needs and model for new therapies.
Neurol Neuroimmunol Neuroinflamm. 2015 Jul 23;2(4):e135. doi: 10.1212/NXI.0000000000000135. eCollection 2015 Aug.
3
Unmet needs of caregivers of severely affected multiple sclerosis patients: A qualitative study.
Palliat Support Care. 2015 Dec;13(6):1685-93. doi: 10.1017/S1478951515000607. Epub 2015 Jun 17.
4
Survival in commercially insured multiple sclerosis patients and comparator subjects in the U.S.
Mult Scler Relat Disord. 2014 May;3(3):364-71. doi: 10.1016/j.msard.2013.12.003. Epub 2013 Dec 25.
5
Unmet care needs of people with a neurological chronic disease: a cross-sectional study in Italy on Multiple Sclerosis.
Eur J Public Health. 2015 Oct;25(5):775-80. doi: 10.1093/eurpub/ckv065. Epub 2015 Mar 30.
6
Unmet needs of multiple sclerosis patients in the community.
Mult Scler Relat Disord. 2015 Mar;4(2):144-50. doi: 10.1016/j.msard.2015.01.003. Epub 2015 Feb 3.
7
Managing psychological stress in the multiple sclerosis medical visit: Patient perspectives and unmet needs.
J Health Psychol. 2016 Aug;21(8):1676-87. doi: 10.1177/1359105314562084. Epub 2014 Dec 19.
8
Outcome measures in multiple sclerosis.
Mult Scler Int. 2014;2014:439375. doi: 10.1155/2014/439375. Epub 2014 May 5.
9
Advances in the treatment of relapsing-remitting multiple sclerosis.
Biomed J. 2014 Mar-Apr;37(2):41-9. doi: 10.4103/2319-4170.130440.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验